Agios Pharm (AGIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $33.07 (-1.61%), Market cap $1.71B, 52-week low–high $22.34 ~ $45.49.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator
Financial statements, price targets, institutional (13F) holdings and related news for Agios Pharm are updated in real time on BlackAll Trade.
Agios Pharm trades at $33.07 (-1.61%). Real-time quotes and charts are available on BlackAll Trade.
Agios Pharm has a market cap of about $1.71B.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an